Trailhead Biosystems, Inc., a biotechnology company focused on creating induced pluripotent stem cell (iPSC)-derived human cells for drug discovery and cell therapy, today announced the launch of TrailBio® A9 Dopaminergic Neurons.
This new product provides researchers with a critical tool for studying Parkinson’s disease and other neurodegenerative conditions.
A9 dopaminergic neurons are essential for regulating movement and are significantly impacted in Parkinson’s disease.
Previously, the lack of viable human models has been a major obstacle in understanding the disease, forcing reliance on less relevant animal studies.
The introduction of TrailBio® A9 Dopaminergic Neurons offers a human-specific platform to investigate disease mechanisms, accelerate drug discovery, and develop new therapies.
“TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson’s research,” said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer, and founder of Trailhead Biosystems. “These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments.”
Trailhead Biosystems utilizes its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, which combines advanced mathematical modeling with high-throughput robotic manufacturing, to produce specialized, high-quality iPSC-derived human cells.
Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems, added, “For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson’s disease. Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies.”
Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead Biosystems is a pioneer in applying an informatics-based approach to regenerative medicine and drug discovery. The company plans to release additional specialized human cell models in the near future.
For more info visit: https://trailbio.com/
